Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals
Preprint
- 7 October 2021
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
Two mRNA vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, were granted the US Food and Drug Administration Emergency Use Authorization for preventing COVID-19. However, little is known about the difference in antibody responses induced by the two mRNA vaccines in naïve and individuals with a previous history of infections (PI group). Therefore, we investigated the levels of anti-S-RBD total antibodies (IgM, IgA, and IgG), anti-S-RBD IgG, and anti-S-RBD IgA in these two groups 1-13 (median=6) weeks following administration of two doses of mRNA-1273 or BNT162b2 vaccines. Results showed that in naïve-vaccinated group, the mRNA-1327 vaccine induces significantly higher levels of S-RBD total antibodies (3.5-fold; p<0.001), S-RBD IgG (2-fold-p<0.01), and S-IgA (2.1-fold, p<0.001) than the BNT162b2 vaccine. In the PI-vaccinated group, both vaccines produce significantly higher S-RBD total antibodies level than those of the naïve-vaccinated group. The PI group produced a higher level of S-RBD IgG than the naïve-BNT162b2 (p=0.05) but not more than the naïve-mRNA-1273 (p=0.9) group. Interestingly, the PI-vaccinated group produced a comparable level of IgA ratio to the naïve-mRNA-1273 group but significantly higher than the naïve-BNT162b2 group (1.6-fold, p<0.001). Our results showed that the mRNA-1327 vaccine is more immunogenic and induces a greater antibody response than the BNT162b2 vaccine.Keywords
Other Versions
- Published version: Version Journal of Travel Medicine, 28, preprints
This publication has 9 references indexed in Scilit:
- Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273JAMA, 2021
- mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in QatarNature Medicine, 2021
- Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 VariantsThe New England Journal of Medicine, 2021
- COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variantsNature Communications, 2021
- Performance of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies in South AfricaPLOS ONE, 2021
- Human IgG and IgA responses to COVID-19 mRNA vaccinesPLOS ONE, 2021
- In search for the SARS-CoV-2 protection correlate: A head-to-head comparison of two quantitative S1 assays in a group of pre-characterized oligo-/asymptomatic patientsPublished by Cold Spring Harbor Laboratory ,2021
- Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-COV-2 IndividualsMicroorganisms, 2021
- IgA dominates the early neutralizing antibody response to SARS-CoV-2Science Translational Medicine, 2021